Sign In
Last checked at 
17 Feb 2022 14:19
GlaxoSmithKline plc (the 'Company')
Deferred Annual Bonus Plan Awards
On 15 February 2022, the Company granted awards to the Persons Discharging Managerial Responsibilities ('PDMRs') listed below. The awards have been granted in accordance with the rules of the GlaxoSmithKline 2017 Deferred Annual Bonus Plan ('DABP') which was approved by shareholders on 4 May 2017.
Executive Directors are required to defer 50% of any bonus earned into Ordinary Shares or American Depositary Shares ('ADSs') for a period of three years. Other members of the GSK Leadership Team are required to defer 25% of any bonus earned into Ordinary Shares or ADSs for the same period.
The awards have been granted as restricted awards over ADSs for US participants and as nil-cost options over Ordinary Shares for all other participants.
The numbers of Ordinary Shares and ADSs shown below are exclusive of dividend reinvestment that will accrue during the deferral period.
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms E Walmsley | |||
b) | Position/status | Chief Executive Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.712 | 72,399 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2022-02-15 | |||
f) | Place of the transaction
| N/A | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr I Mackay | |||
b) | Position/status | Chief Financial Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.712 . | 50,056 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2022-02-15 | |||
f) | Place of the transaction
| N/A | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr H Barron | |||
b) | Position/status | Chief Scientific Officer and President, R&D | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W1053 | |||
b) | Nature of the transaction | Deferred Bonus Award of ADSs under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| $42.87 | 40,617 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2022-02-15 | |||
f) | Place of the transaction
| N/A | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr R Connor | |||
b) | Position/status | President, Vaccines and Global Health | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.712 . | 12,300 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2022-02-15 | |||
f) | Place of the transaction
| N/A | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms D Conrad | |||
b) | Position/status | Chief People Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.712 . | 11,370 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2022-02-15 | |||
f) | Place of the transaction
| N/A | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr J Ford | |||
b) | Position/status | SVP and General Counsel | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.712 . | 13,998 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2022-02-15 | |||
f) | Place of the transaction
| N/A | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms S Jackson | |||
b) | Position/status | SVP, Global Communications and CEO Office | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.712
| 6,537 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2022-02-15 | |||
f) | Place of the transaction
| N/A | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr B McNamara | |||
b) | Position/status | CEO, GSK Consumer Healthcare | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W1053 | |||
b) | Nature of the transaction | Deferred Bonus Award of ADSs under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| $42.87 | 4,306 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2022-02-15 | |||
f) | Place of the transaction
| N/A | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr L Miels | |||
b) | Position/status | Chief Commercial Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.712 . | 23,796 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2022-02-15 | |||
f) | Place of the transaction
| N/A | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms S Ramakrishnan | |||
b) | Position/status | Chief Digital and Technology Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W1053 | |||
b) | Nature of the transaction | Deferred Bonus Award of ADSs under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| $42.87 . | 2,482 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2022-02-15 | |||
f) | Place of the transaction
| N/A | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr D Redfern | |||
b) | Position/status | Chief Strategy Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.712 . | 15,783 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2022-02-15 | |||
f) | Place of the transaction
| N/A | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr R Simard | |||
b) | Position/status | President, Pharmaceuticals Supply Chain | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.712 . | 14,336 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2022-02-15 | |||
f) | Place of the transaction
| N/A | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr P Thomson | |||
b) | Position/status | President, Global Affairs | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.712 . | 9,947 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2022-02-15 | |||
f) | Place of the transaction
| N/A | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms D Waterhouse | |||
b) | Position/status | CEO, ViiV Healthcare | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.712 . | 10,498 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2022-02-15 | |||
f) | Place of the transaction
| N/A | |||
Follow the stocks
